Back to top
more

AN2 Therapeutics (ANTX)

(Delayed Data from NSDQ)

$2.56 USD

2.56
168,361

+0.02 (0.79%)

Updated May 3, 2024 04:00 PM ET

After-Market: $2.55 -0.01 (-0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why

AN2 Therapeutics, Inc. (ANTX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why

AN2 Therapeutics, Inc. (ANTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Novo Nordisk, Lifeway Foods, Casey's in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?

Continued strategic executions on the United States and the international fronts are likely to drive Walgreens (WBA) Q4 revenues.

Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.

Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?

Here is how AN2 Therapeutics, Inc. (ANTX) and Artivion (AORT) have performed compared to their sector so far this year.

J&J (JNJ) Seeks Full FDA Nod for Rybrevant in Lung Cancer

J&J's (JNJ) FDA filing is based on a late-stage study showing that treatment with Rybrevant plus chemotherapy improved progression-free survival in certain NSCLC patients.

J&J (JNJ) to Keep 9.5% Stake in Kenvue Post Share Exchange

J&J's (JNJ) offer to exchange its shares for the shares of Kenvue, its recently-separated consumer healthcare business, gets oversubscribed. The exchange ratio is 8.0324 for every share of J&J.